There is a discussion about second-line therapies for chronic inflammatory demyelinating polyneuropathy (cidp) when initial treatments are not sufficient. The focus is on alternatives to intravenous immunoglobulin (ivig). The consideration of these additional therapies suggests that ivig may not be effective for all cidp patients.